JAMA Neurology : Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease
Interview with John Sims, author of Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"JAMA Network","authorlink":""},"src":"http:\/\/traffic.libsyn.com\/jamaneurologyauthorinterviews\/Efficacy_and_Safety_of_Lanabecestat_for_Treatment_of_Early_and_Mild_Alzheimer_Disease.mp3","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202106\/652e00-107e-0f7a-72a237_800.jpg"},"title":"JAMA Neurology : Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease","link":"javascript:;","id":"item-257738"}]
